Effective end-organ protection in arterial hypertension: possibilities of third-generation calcium antagonists
More details
Hide details
First Moscow State Medical University named after I. M. Sechenov, Moscow, Russia
Shchekino Regional Hospital, Tula, Russia
Publish date: 2018-07-10
Electron J Gen Med 2018;15(4):em65
Arterial hypertension (AH) is one of the most common and socially significant diseases worldwide. Despite years of experience gained in studying hypertension, the problems concerning selection of antihypertensive therapy with pleiotropic organ-protecting effects are still of current importance. The purpose of the study was to assess therapeutic efficacy and pleiotropic organ-protective capability of third-generation calcium antagonist lercanidipine in patients with stage 2-3 hypertension.

Our study enrolled a total of ninety-two 31-to-84-year-old patients. Of these, 72 patients diagnosed as having stage 2 or 3 AH composed the Study Group and 20 apparently healthy subjects were included into the Control Group. At baseline and after 6 months, all patients of the Study Group underwent examinations consisting in measuring biochemical parameters [total cholesterol (TCH), triglycerides (TG), low-density lipoprotein cholesterol (LDL CH), uric acid, urea, creatinine, glucose], 24-hour ambulatory BP monitoring, echocardiography (EchoCG) in order to assess the dimensions and volume of the cardiac chambers, thickness of the left ventricular posterior wall (LVPW) and left-ventricular myocardium mass index (LVMMI), studying microalbuminuria (MAU) , a known marker of endothelial dysfunction and early renal lesion; assessing the state of the vascular wall by the ankle-brachial index (ABI) and pulse pressure (PP). Antihypertensive therapy consisted in lercanidipine alone taken at a dose of 10-20 mg/day, failure to thereby achieve the target BP level was followed by additionally prescribing an angiotensin converting enzyme (ACE) inhibitor, enalapril, given at a dose of 5-20 mg twice daily.

All patients by the end of the study achieved the target level of AP (p<0.05), also demonstrating significantly improved (p<0.01) parameters of endothelial dysfunction and an early marker of renal damage (MAU), indices of elastic properties of the vascular wall ABI (p<0.05) and PP (p=0.01). Significantly positive dynamics was observed for the following parameters: decreased creatinine concentration (p<0.001), increased GFR (p<0.001), decreased levels of TCH (p<0.01) and LDL CH (p<0.001).

Lercanidipine therapy of patients with stage 2 - 3 AH proved highly efficient, well tolerated, metabolically neutral with pleiotropic organ-protecting properties in the form of improved condition of the vascular wall, correction of endothelial dysfunction, nephroprotective action.

1. Kearney PM. Global burden of hypertension: analysis of worldwide data. The Lancet. 2005;365(9455): 217-23. https://doi.org/10.1016/S0140-....
2. Zhukovsky GS, Konstantinov VV, VarlamovaTA. Arterial hypertension: epidemiological situation in Russia and other countries. Russian Medical Journal. 1997;9:551-58 [in Russian].
3. Expert Committee of the All-Russian Scientific Society of Cardiology. Section of Arterial Hypertension. Prevention, diagnosis and treatment of arterial hypertension. 2004;10:142-153.
4. Diagnosis and treatment of arterial hypertension. Russian guidelines. 4th revision. Systemic Hypertensions. 2010;3:5-26.
5. Preobrazhensky DV, Sidorenko BA, Dedova IS, Shaipova AM, Tarykina EV. Lercanidine – a new third-generation calcium antagonist: clinical pharmacology and experience in using for treatment of arterial hypertension. Regular issues of the Russian Medical Journal. 2016;20:1411-1421.
6. Lukina YuV, Martsevich SYu. Positions of calcium antagonist lercanidipine according to evidence-based medicine. Rational Pharmacotherapy in Cardiology. 2010;(6)4:558-64. https://doi.org/10.20996/1819-....
7. Romito R, Pansini MI, Perticone F. Comparative effect of lercanidipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension. The Lercanidipine in Adults (LEAD) Study, J Clin Hypertens (Greenwich). 2003;5(4):249-53. https://doi.org/10.1111/j.1524....
8. Barrios V, Navarro A, Esteras A. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press.2002;11(2):95–100. https://doi.org/10.1080/080370....
9. Zanchetti A. Emerging data on calcium-channel blockers: the COHORT study. Clin Cardiol. 2003;26:2:17–20. https://doi.org/10.1002/clc.49....
10. Belgian Physical Fitness, Cardiovascular Health, Edinburgh Artery, Framingham Offspring, Health in Men, Honolulu Heart Program, Hoorn, InCHIANTI, Limburg PAOD, Men Born in 1914. Rotterdam: Strong Heart.
11. Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta–analysis. JAMA. 2008;300(2):197–208. https://doi.org/10.1001/jama.3....
12. Elfimova EV, Zairova AR, Andrievskaya MV. Effect of combined antihypertensive therapy on arterial wall stiffness in male patients with arterial hypertension, obesity and obstructive sleep apnea syndrome. Systemic Hypertensions. 2016;13(4):36–40.
13. Abernethy J, Borbani NO, Hawrins CM. Systolic blood pressure as an independent predictor of mortality in the Hypertension Detection and Follow-up Program. Am J Prev Med. 1986;2:123-32.
14. Chukaeva II, Solovieva MV, Spiryakina YaG. Significance of pulsatile arterial pressure in treatment of hypertensive patients: possibilities of using indapamide SR. Consilium Medicum. 2014;16(10):5-8.
15. Benetos A, Safar M. Pulse pressure. A predictor of long-term cardio-vascular mortality in a French male population. Hypertension. 1997;30(6):1410–5. https://doi.org/10.1161/01.HYP....
16. Dzizinskiy AA, Protasov KV, Sinkevich D A, Kozhevnikova EE, Fedorishina OV. Pulse pressure as a risk factor for target organ damage in patients with arterial hypertension. Siberian Medical Journal. 2009;(90)7:27-30 [in Russian].
17. Borghi C. Lercanidipine in hypertension. Vascular Health Risk Management. 2005;1:173–82.
18. Volpe M. Microalbuminuria screening in patients with hypertension: Recommendations for clinical practice. Int J Clin Pract. 2008;62(1):97–108. https://doi.org/10.1111/j.1742....
19. Karalliedde J, Viberti G. Microalbuminuria and cardiovascular risk. Am J Hypertens. 2004;17(10):986–93. https://doi.org/10.1016/j.amjh....
20. Pedrinelli R, Dell’Omo G, Di Bello V. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens. 2002;16:79–89. https://doi.org/10.1038/sj.jhh....
21. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med.2000; 342(3):145–53. https://doi.org/10.1056/NEJM20....
22. Moiseev VS, Mukhin NA, Kobalava ZhD. Functional state of the kidneys and prediction of cardiovascular risk. Cardiovascular Surgery and Prevention. 2008;7(6):1-20.
23. Vestra MD, Pozza G, Mosca A. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (Diabete, Ipertensione, Albuminuria, Lercanidipina). Diab Nutr Metab. 2004;1(7):259-66.
24. Shilov AM. Place of third-generation calcium channel blockers in the continuum of metabolic syndrome. The Difficult Patient. 2014;(4):20-5.
25. Robles NR, Ocon J, Gomez CF. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail. 2005;27(1):73–80. https://doi.org/10.1081/JDI-42....